Connection

Matteo Bassetti to Pseudomonas aeruginosa

Back to Details
This is a "connection" page, showing publications Matteo Bassetti has written about Pseudomonas aeruginosa.
Matteo Bassetti
Connection Strength
3.132
Pseudomonas aeruginosa
  1. Rational approach in the management of Pseudomonas aeruginosa infections. Curr Opin Infect Dis. 2018 12; 31(6):578-586.
    View in: PubMed
    Score: 0.519
  2. Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience. Int J Antimicrob Agents. 2019 Apr; 53(4):408-415.
    View in: PubMed
    Score: 0.516
  3. Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug- resistant/extensively drug-resistant/pandrug-resistant bacteria. Curr Opin Crit Care. 2018 10; 24(5):385-393.
    View in: PubMed
    Score: 0.513
  4. Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant. Infection. 2018 Apr; 46(2):263-265.
    View in: PubMed
    Score: 0.481
  5. Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane/tazobactam. J Glob Antimicrob Resist. 2017 06; 9:100-102.
    View in: PubMed
    Score: 0.465
  6. Bloodstream infections in critically ill patients with COVID-19. Eur J Clin Invest. 2020 Oct; 50(10):e13319.
    View in: PubMed
    Score: 0.146
  7. The ideal patient profile for new beta-lactam/beta-lactamase inhibitors. Curr Opin Infect Dis. 2018 12; 31(6):587-593.
    View in: PubMed
    Score: 0.130
  8. Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers. J Antimicrob Chemother. 2018 03 01; 73(3):664-671.
    View in: PubMed
    Score: 0.123
  9. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15). J Antimicrob Chemother. 2017 05 01; 72(5):1386-1395.
    View in: PubMed
    Score: 0.116
  10. [Diagnostic and therapeutic management of Gram-negative infections]. Infez Med. 2008 Apr; 16 Suppl2:22-9.
    View in: PubMed
    Score: 0.062
  11. Risk Factors and Outcomes of Endocarditis Due to Non-HACEK Gram-Negative Bacilli: Data from the Prospective Multicenter Italian Endocarditis Study Cohort. Antimicrob Agents Chemother. 2018 04; 62(4).
    View in: PubMed
    Score: 0.031
  12. Ceftolozane/tazobactam: place in therapy. Expert Rev Anti Infect Ther. 2018 04; 16(4):307-320.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.